OakChart

Keros Therapeutics Inc

KROSHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

9.54+0.21 (2.25%)
2026-11-12 01:53 CET
Market cap
183.10 USD m
Revenue, TTM
40.76 USD m
Net income, TTM
-61.73 USD m
Free cash flow, TTM
-48.27 USD m
EPS diluted, TTM
-2.82
P/E
-
Compare

Price

KROS against its 20, 50 and 200-day averages
2050200beatmiss
10.0012.0014.00713K1.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26KROSclose 9.5420-day 10.7050-day 11.08200-day 11.709.5452w low

57.7% under the 52-week high of 22.55 on 8 Dec 2025. 52-week low 8.98 on 10 Nov 2026. Last 15 sessions, 32.3% high to low

Volume 1.24× normal · the line is the 50-bar volume average

Profile

KROS
52-week range, 4% of the way up
8.9822.55

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.

IndexRUT
Employees78
IPOApr 08, 2020
Beta1.21
ATR, 14d0.60
Rel volume1.24
Short float6.05%
Insider own8.45%
Inst own91.70%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap187.22M
Enterprise Value-57.13M
Income-61.73M
Sales40.76M
Book/sh14.07
Cash/sh13.22
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees78
IPOApr 08, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S4.59
P/B0.68
P/C0.72
P/FCF-
EV/EBITDA-
EV/Sales-1.40
Quick Ratio18.14
Current Ratio18.14
Debt/Eq0.05
LT Debt/Eq0.04
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.82
EPS next Y-5.41
EPS next Q-1.63
EPS this Y-269.52%
EPS next Y-38.75%
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y- -
EPS Y/Y TTM-277.31%
Sales Y/Y TTM-83.48%
EPS Q/Q488.28%
Sales Q/Q180.53%
EarningsNov 05 AMC
EPS/Sales Surpr.174.53% 170.98%

Ownership

Insider Own8.45%
Insider Trans-0.85%
Inst Own91.70%
Inst Trans-3.61%
ROA-11.76%
ROE-12.56%
ROIC-21.17%
Gross Margin96.10%
Oper. Margin-179.54%
Profit Margin-151.43%
SMA20-10.87%
SMA50-13.87%
SMA200-18.48%
Trades-

Technical

Shs Outstand19.83M
Shs Float17.97M
Short Float6.05%
Short Ratio6.06
Short Interest1.09M
52W High22.55 -57.69%
52W Low8.98 6.24%
Volatility8.63% 5.49%
ATR (14)0.60
RSI (14)33.73
Beta1.21
Rel Volume1.24
Avg Volume179.35K
Volume221,676

Performance

Perf Week-11.91%
Perf Month-15.05%
Perf Quarter-10.51%
Perf Half Y-20.43%
Perf YTD-53.14%
Perf Year-43.55%
Perf 3Y-67.74%
Perf 5Y-83.92%
Perf 10Y-
Recom1.86
Target Price19.83
Prev Close9.33
Price9.54
Change %2.25%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 20, 2025InitiatedWWells FargoOverweight$26+172.5%
Jun 10, 2025DowngradeBBofA SecuritiesBuy → Neutral$18+88.7%
Jan 21, 2025DowngradeCCantor FitzgeraldOverweight → Neutral
Jan 17, 2025DowngradeWWedbushOutperform → Neutral$15+57.2%
Dec 16, 2024ReiteratedOOppenheimerOutperform$102 → $63+560.4%
Dec 16, 2024DowngradeGGuggenheimBuy → Neutral
Dec 13, 2024ReiteratedHH.C. WainwrightBuy$100 → $47+392.7%
Dec 12, 2024DowngradeWWilliam BlairOutperform → Mkt Perform
Dec 12, 2024DowngradeTTD CowenBuy → Hold
Dec 12, 2024DowngradeBBTIG ResearchBuy → Neutral

Peers

Mkt cap
TickerCompanyMkt cap
SRRKScholar Rock Holding Corp5.68B
CAPRCapricor Therapeutics Inc652.32M
EWTXEdgewise Therapeutics Inc5.21B
TRDAEntrada Therapeutics Inc212.98M
SLDBSolid Biosciences Inc848.24M
DYNDyne Therapeutics Inc3.37B
SRPTSarepta Therapeutics Inc1.79B
WVEWave Life Sciences Inc674.52M
GERNGeron Corp657.13M
IRONDisc Medicine Inc3.97B

Insider trading

latest 14 of 25
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Tanini AnnitaCorp. Controller & VP, FinanceAug 18 '26Sale10.291,22412,59545,144Aug 20 04:10 PM
Lerner Lorena RaquelChief Scientific OfficerAug 18 '26Sale10.293,56836,71527,559Aug 20 04:10 PM
Cho EstherChief Legal OfficerAug 18 '26Sale10.294,48546,15135,770Aug 20 04:10 PM
Newton Charles W.DirectorAug 18 '26Sale10.305515,67512,114Aug 20 04:10 PM
BIENAIME JEAN JACQUESDirectorAug 17 '26Buy10.271,00010,27019,592Aug 19 04:10 PM
Newton Charles W.DirectorAug 18 '26Proposed Sale10.385515,719Aug 18 04:11 PM
BIENAIME JEAN JACQUESDirectorJul 15 '26Buy10.611,00010,61018,592Jul 17 04:10 PM
BIENAIME JEAN JACQUESDirectorJun 15 '26Buy10.191,00010,19017,592Jun 17 04:55 PM
Newton Charles W.DirectorJun 11 '26Sale10.045505,52212,665Jun 15 04:15 PM
Newton Charles W.DirectorJun 11 '26Proposed Sale9.955505,472Jun 11 04:15 PM
Farzan NimaDirectorJun 04 '26Sale10.732,62528,1669,767Jun 08 04:37 PM
Knowles JuliusDirectorJun 04 '26Sale10.732,62528,16610,958Jun 08 04:36 PM
Seth AlpnaDirectorJun 04 '26Sale10.722,62528,1409,767Jun 05 04:15 PM
Farzan NimaDirectorJun 04 '26Proposed Sale10.682,62528,035Jun 04 04:11 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
DFSVUS Small Cap Value Portfolio ETF Class SharesAUM: 8.52B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SMLFiShares U.S. Small-Cap Equity Factor ETFAUM: 4.26B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
BSVOEA Bridgeway Omni Small-Cap Value ETFAUM: 2.44B

News

latest 14 of 200
  • Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial Results (GlobeNewswire) -12.74%
  • A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday (PR Newswire)
  • Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda (GlobeNewswire)
  • Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD (GlobeNewswire)
  • Keros Therapeutics Announces $5 Million Share Repurchase Authorization (GlobeNewswire)
  • Keros Therapeutics Reports Second Quarter 2026 Financial Results (GlobeNewswire)
  • Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda (GlobeNewswire)
  • Keros Therapeutics Appoints Anne Prener to its Board of Directors (GlobeNewswire) +5.57%
  • Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire)
  • Keros Therapeutics Reports Recent First Quarter 2026 Financial Results (GlobeNewswire) -8.34%
  • Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference (GlobeNewswire)
  • Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS (GlobeNewswire)
  • Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market? (Zacks)
  • Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline? (Zacks) -14.96%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-050.700-0.9390.70040.0114.767
2026Q22026-08-03-1.450-1.340-1.4500.000.817
2026Q12026-05-14-1.210-1.023-1.2080.371.937
2025Q42026-03-04-0.860-0.697-0.8630.393.677
2025Q32025-11-05-0.180-1.135-0.17914.264.759
2025Q22025-08-06-0.760-1.110-0.75618.174.0211
2025Q12025-05-063.620-1.1543.619211.251.877
2024Q42025-02-26-1.140-1.356-1.1413.040.0512
2024Q32024-11-06-1.410-1.279-1.4090.390.0016
2024Q22024-08-07-1.250-1.259-1.2540.040.0011
2024Q12024-05-08-1.210-1.333-1.2080.080.0011
2023Q42024-02-28-1.340-1.374-1.3360.140.0011
2023Q32023-11-06-1.330-1.348-1.3290.010.009
2023Q22023-08-07-1.270-1.339-1.2670.000.229
2023Q12023-05-04-1.260-1.123-1.2620.000.337
2022Q42023-03-03-1.090-1.097-1.0880.001.207

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-4.987--0.7027.50-
2020FY-2.930-4.145-2.9250.000.00
2021FY-2.520-3.143-2.51820.100.10
2022FY-4.150-4.163-4.1470.001.00
2023FY-5.200-5.240-5.1960.150.00
2024FY-5.000-5.189-5.0043.550.55
2025FY2.3002.2992.300244.06245.93
2026FY--3.899--29.76
2027FY--5.410--16.30
2028FY--4.367--44.69
2029FY--3.577--70.96
2030FY--1.542--119.52

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-067000.480.003.00
2026Q4S2026-11-057000.480.003.00
2026Q4S2026-08-207000.480.003.00
2026Q4S2026-08-048010.620.003.00
2026Q4S2026-08-017000.780.003.00
2026Q4S2026-07-287010.780.003.00
2026Q4S2026-06-137110.780.003.00
2026Q4S2026-06-038110.680.003.00
2026Q4S2026-05-197110.780.003.00
2026Q4S2026-05-187120.780.003.00
2026Q4S2026-05-147110.800.003.00
2026Q4S2026-03-057010.500.003.00
2026Q4S2026-01-204000.640.002.54
2026Q4S2025-11-114100.640.002.54

Estimate history

EPS, annual-0.124-0.702-2.925-2.518-4.147-5.196-5.0042.298-2.8245
Period20182019202020212022202320242025TTM
EPS, quarterly-1.409-1.1413.619-0.756-0.179-0.863-1.208-1.450.696
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual1010020.100.1513.55244.06140.76
Period20182019202020212022202320242025TTM
Sales, quarterly0.3883.042211.24618.16814.2620.3850.367040.009
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual18.93920.14923.19323.97527.54331.84140.55519.54419.831
Period20182019202020212022202320242025MRQ
Shares, quarterly39.25840.55540.56240.61540.63219.54419.73319.82719.831
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue40.76244.063.550.150.0020.100.0010.0010.00
Cost of Goods Sold Incl. D&A1.591.511.230.811.610.900.60--
Gross Profit39.17242.552.32-0.66-1.6119.20-0.60--
Selling, General and Administrative Excl. Other112.36171.93213.15169.28113.1775.5846.0520.1211.39
Research and Development76.75127.09173.63135.2687.2755.1433.8617.3810.11
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-73.1870.62-210.83-169.94-114.79-56.37-46.66-10.56-1.69
Interest Expense0.000.000.000.000.000.000.010.01-
Unusual Expense0.083.050.000.000.000.001.492.560.04
Net Income Before Taxes-62.4791.90-187.05-152.99-104.68-56.73-45.53-12.34-1.08
Income Taxes-0.744.880.300.000.002.01-0.170.000.26
Consolidated Net Income-61.7387.01-187.35-152.99-104.68-58.74-45.36-12.34-1.33
Net Income From Continuing Operations-61.7387.01-187.35-152.99-104.68-58.74-45.36-12.34-1.33
Net Income-61.7387.01-187.35-152.99-104.68-58.74-45.36-14.14-2.35
EPS (Recurring)-3.032.35-5.00-5.20-4.15-2.52-2.86-0.61-0.12
EPS (Basic, Before Extraordinaries)-2.812.34-5.00-5.20-4.15-2.52-2.93-0.70-0.12
EPS (Diluted)-2.822.30-5.00-5.20-4.15-2.52-2.93-0.70-0.12
EBITDA-71.5972.13-209.60-169.13-113.17-55.48-46.05-10.12-1.39
Non-Operating Income (Expense)10.8024.3323.7816.9510.11-0.362.620.800.66
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense20.6722.6727.5528.7618.688.562.990.040.06
Price To Sales Ratio5.693.16166.947,753.76-67.92---
Gross Margin96.1099.3865.38-439.74-95.53---
Operating Margin-179.5428.94-5,938.96-112,543.71--280.46--105.63-16.91
Net Margin-151.4335.65-5,277.55-101,319.21--292.26--141.36-23.46
Shares Outstanding19.8319.5440.5531.8427.5423.9723.1920.1518.94
Market Capitalization183.10183.10641.231,191.191,322.631,369.061,424.081,455.17-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue40.010.000.370.3914.2618.17211.253.04
Cost of Goods Sold Incl. D&A0.380.400.400.400.400.370.340.33
Gross Profit39.62-0.40-0.04-0.0113.8717.80210.902.71
Selling, General and Administrative Excl. Other26.8130.5425.8429.1729.2557.6258.8655.96
Research and Development20.4922.3316.1017.8319.5243.5048.7145.63
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income12.82-30.94-25.88-29.19-15.38-39.82152.04-53.25
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.080.000.000.000.00
Net Income Before Taxes14.93-28.71-23.71-24.98-8.70-32.92158.49-45.73
Income Taxes0.770.000.00-1.51-1.42-2.2210.040.30
Consolidated Net Income14.15-28.71-23.71-23.46-7.28-30.70148.45-46.03
Net Income From Continuing Operations14.15-28.71-23.71-23.46-7.28-30.70148.45-46.03
Net Income14.15-28.71-23.71-23.46-7.28-30.70148.45-46.03
EPS (Recurring)0.70-1.45-1.21-0.86-0.18-0.763.62-1.14
EPS (Basic, Before Extraordinaries)0.71-1.45-1.21-0.86-0.18-0.763.66-1.14
EPS (Diluted)0.70-1.45-1.21-0.86-0.18-0.763.62-1.14
EBITDA13.20-30.54-25.47-28.79-14.99-39.45152.38-52.92
Non-Operating Income (Expense)2.112.232.174.296.686.906.457.53
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.325.386.205.773.156.757.007.27
Price To Earnings Ratio--6.0613.2050.49---
Price To Sales Ratio5.6914.116.532.272.602.331.95179.87
Gross Margin99.04--9.81-3.9097.2397.9699.8489.09
Operating Margin32.04--7,050.95-7,581.04-107.87-219.1671.97-1,750.62
Net Margin35.37--6,459.95-6,093.77-51.04-168.9670.27-1,513.02
Shares Outstanding19.8319.8319.7319.5440.6340.6240.5640.55
Market Capitalization183.10211.77217.68620.29642.54542.22413.33641.23

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments287.42559.93331.15279.05230.04265.887.0223.26
Short Term Receivables6.374.461.090.8418.200.220.920.00
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets21.6524.5115.055.883.201.630.382.27
Total Current Assets315.43588.89347.29285.77251.44267.738.3225.53
Net Property, Plant & Equipment21.1423.4919.4717.572.401.601.911.38
Total Investments and Advances1.451.451.211.331.330.120.120.13
Long-Term Note Receivable------0.000.37
Intangible Assets0.00----0.000.000.00
Deferred Tax Assets4.85-------
Other Assets0.002.062.052.120.080.000.600.00
Total Assets342.87615.89370.02306.78255.25269.4410.9627.41
Short Term Debt Incl. Current Port. of LT Debt2.411.981.000.460.860.420.380.17
Accounts Payable1.974.605.453.343.652.152.090.50
Income Tax Payable---0.050.110.180.040.28
Other Current Liabilities16.0420.8717.9212.707.234.431.9810.52
Total Current Liabilities20.4127.4524.3716.5511.857.184.4911.47
Long Term Debt14.4716.8813.4412.810.230.4825.8022.95
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Deferred Tax Liabilities4.85-------
Other Liabilities0.000.000.000.000.000.060.120.17
Total Liabilities39.7444.3337.8129.3612.087.7230.4034.59
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity303.13571.55332.21277.42243.17261.72-19.45-7.18
Total Shareholders Equity303.13571.55332.21277.42243.17261.72-19.45-7.18
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity303.13571.55332.21277.42243.17261.72-19.45-7.18
Total Liabilities & Stockholders Equity342.87615.89370.02306.78255.25269.4410.9627.41
Book Value Per Share15.5114.0910.4310.0710.1411.28-0.97-0.38
Tangible Book Value Per Share15.5114.0910.4310.0710.1411.28-0.97-0.38
Full-Time Employees78169136105603523-
Price to Book Ratio0.661.173.995.205.776.2511.13-
Return on Assets18.15-38.01-45.21-37.25-22.39-32.35-64.31-
Return on Equity19.90-41.46-50.19-40.21-23.27-37.45--
Return on Invested Capital27.40-31.84-44.26-36.07-24.13-17.30-194.27-8.46
Quick Ratio15.4521.4514.2517.2721.2337.271.862.23
Current Ratio15.4521.4514.2517.2721.2337.271.862.23

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-61.7387.01-187.35-152.99-104.68-58.74-45.36-12.34-1.33
Depreciation1.591.511.230.811.610.900.600.440.30
Other Funds (Non Cash)25.6631.0936.6930.3218.6911.775.592.620.12
Funds from Operations-34.48119.62-149.43-121.86-84.37-46.08-39.17-9.27-0.91
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-13.38-12.11-11.44-2.6514.31-16.072.27-6.727.95
Cash from Operating Activities-47.85107.50-160.87-124.51-70.06-62.15-36.89-16.007.04
Capital Expenditures-0.42-1.55-1.93-2.46-1.24-1.02-0.29-0.27-0.22
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.42-1.55-1.93-2.46-1.24-1.02-0.29-0.27-0.22
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-380.07-378.47391.82178.96120.3128.55296.040.0111.46
Repurchase of Common Pref Stock-376.55-375.000.000.000.000.000.000.000.00
Sale of Common Pref Stock-3.53-3.47391.82178.96120.3128.55296.040.0111.46
Proceedsfrom Stock Options-3.69-3.62379.68175.73119.4928.17296.230.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-5.660.000.000.000.000.000.000.000.00
Other Financing Activities Uses-5.660.000.000.000.000.000.000.000.00
Cash from Financing Activities-385.74-378.47391.82178.96120.3128.55296.040.0111.46
Net Change in Cash-434.01-272.52229.0251.9849.01-34.62258.86-16.2518.29
Free Cash Flow-48.27105.95-162.80-126.97-71.30-63.17-37.19-16.276.83
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00--
Price to Free Cash Flow-7.27-------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments259.46257.61281.50287.42693.47690.22
Short Term Receivables22.842.762.966.375.5717.74
Inventories0.000.000.000.000.000.00
Other Current Assets5.336.526.2221.6520.2724.85
Total Current Assets287.63266.88290.68315.43719.31732.81
Net Property, Plant & Equipment18.2819.2720.1721.1422.0322.91
Total Investments and Advances1.451.451.451.451.451.45
Intangible Assets-0.000.000.000.000.00
Deferred Tax Assets---4.85--
Other Assets0.010.000.000.000.000.00
Total Assets307.37287.60312.29342.87742.78757.16
Short Term Debt Incl. Current Port. of LT Debt2.692.602.502.412.322.23
Accounts Payable3.791.821.491.972.305.27
Income Tax Payable0.61-----
Other Current Liabilities8.767.748.8616.0419.4827.21
Total Current Liabilities15.8612.1512.8520.4124.0934.71
Long Term Debt12.4113.1313.8114.4715.1115.72
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---4.85--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities28.2725.2826.6639.7439.2050.43
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity279.10262.32285.63303.13703.58706.73
Total Shareholders Equity279.10262.32285.63303.13703.58706.73
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity279.10262.32285.63303.13703.58706.73
Total Liabilities & Stockholders Equity307.37287.60312.29342.87742.78757.16
Book Value Per Share14.0713.2314.4715.5117.3217.40
Tangible Book Value Per Share14.0713.2314.4715.5117.3217.40
Full-Time Employees-92-78-148
Price to Book Ratio0.660.740.711.180.910.74
Return on Assets-11.76-15.92-15.5318.159.753.10
Return on Equity-12.56-17.16-16.7919.9010.433.33
Return on Invested Capital4.86-10.42-7.92-7.39-1.01-4.25
Quick Ratio18.1421.9622.6215.4529.8621.11
Current Ratio18.1421.9622.6215.4529.8621.11

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income14.15-28.71-23.71-23.46-7.28-30.70
Depreciation0.380.400.400.400.400.37
Other Funds (Non Cash)4.876.036.837.934.599.12
Funds from Operations19.41-22.28-16.47-15.13-2.29-21.20
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-16.021.8612.94-12.165.54-8.42
Income Taxes Payable0.610.000.00--2.17-3.72
Cash from Operating Activities3.39-20.42-3.53-27.293.25-29.62
Capital Expenditures-0.06-0.15-0.07-0.13-0.13-0.72
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.06-0.15-0.07-0.13-0.13-0.72
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-1.470.020.01-378.630.140.02
Repurchase of Common Pref Stock-1.540.000.00-375.000.000.00
Sale of Common Pref Stock0.070.020.01-3.630.140.02
Proceedsfrom Stock Options0.070.000.00-3.760.140.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.00-3.34-2.320.000.000.00
Other Financing Activities Uses-0.00-3.34-2.320.000.000.00
Cash from Financing Activities-1.47-3.31-2.32-378.630.140.02
Net Change in Cash1.86-23.89-5.92-406.063.26-30.33
Free Cash Flow3.33-20.58-3.60-27.433.12-30.34
Price to Free Cash Flow---5.237.3810.21

Revenue breakdown

License2024: 3.00M 2025: 205.36M
Service, Other2024: 550.00K 2025: 38.71M
United States2024: 3.55M 2025: 244.06M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-306.05%1.1M18.0M188.05K
2026-10-156.26%1.1M18.2M190.37K
2026-09-306.33%1.1M18.2M203.96K
2026-09-157.40%1.3M18.2M235.57K
2026-08-316.43%1.2M18.1M245.69K
2026-08-146.34%1.1M18.1M272.48K
2026-07-315.42%1.0M18.2M288.51K
2026-07-155.84%1.1M18.1M308.03K
2026-06-305.65%1.0M18.2M333.43K
2026-06-157.75%1.4M18.2M365.05K
2026-05-298.28%1.5M18.2M424.15K
2026-05-159.35%1.7M18.2M424.75K
2026-04-307.84%1.4M18.1M409.80K
2026-04-157.51%1.4M18.7M410.98K
2026-03-318.02%1.5M18.7M418.13K
2026-03-1310.67%2.0M18.7M413.26K
2026-02-277.05%2.0M28.8M474.71K
2026-02-138.24%2.4M28.9M628.42K
2026-01-307.87%2.3M28.9M790.07K
2026-01-158.11%2.3M28.9M935.70K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.504.509.000.0020.1100.000.000.985-0.0160.001
call5.002.306.500.009.5230.000.000.970-0.0150.001
call7.500.104.900.007.6250.000.000.934-0.0130.002
call10.000.002.450.004.4950.000.000.582-0.1210.006
call12.500.004.900.2910.8411.000.000.750-0.2740.005
call15.000.003.200.006.5150.000.000.525-0.2180.006
call17.500.004.900.008.6910.000.000.585-0.2690.006
call20.000.004.900.009.1900.000.000.575-0.2860.006
put2.500.000.950.004.7980.000.00-0.015-0.0150.001
put5.000.000.050.002.2870.000.00-0.032-0.0130.001
put7.500.000.100.001.0920.000.00-0.066-0.0120.002
put10.000.251.200.651.4161360.00-0.418-0.1200.006
put12.501.005.400.005.6870.000.00-0.445-0.1870.006
put15.003.508.000.006.6940.000.00-0.475-0.2170.006
put17.506.0010.500.007.3370.000.00-0.495-0.2380.006
put20.008.5013.000.007.8610.000.00-0.509-0.2550.006

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-058-KCurrent report2026-11-05SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-27SCHEDULE 13G/ASEC
2026-09-298-KCurrent report2026-09-29SEC
2026-09-288-KCurrent report2026-09-28SEC
2026-09-16EFFECTEffectiveness filing by commission orderSEC
2026-09-11DEL AMSeparately filed delaying amendment under Securities Act Rule 473 to delay effectiveness of a 1933 Act registration statementSEC
2026-09-10S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-09-088-KCurrent report2026-09-08SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-18144Filing for proposed sale of securities under Rule 144.SEC
2026-08-133Initial statement of beneficial ownership of securities2026-08-04SEC
2026-08-038-KCurrent report2026-08-03SEC
2026-08-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-038-KCurrent report2026-08-03SEC
2026-07-308-KCurrent report2026-07-30SEC
2026-07-29SCHEDULE 13G/ASEC
2026-07-228-KCurrent report2026-07-17SEC
2026-07-17SCHEDULE 13GSEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-063Initial statement of beneficial ownership of securities2026-07-01SEC
2026-06-258-KCurrent report2026-06-23SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-0810.27K1101.14K4
2026-0710.61K100
2026-0610.19K189.99K4
2026-0510.58K100
2026-0411.70K100
2026-0322.42K100
2026-0200331.82K4
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Nantahala Capital Management, LLC14.25%
BlackRock, Inc.14.12%
AQR CAPITAL MANAGEMENT LLC4.89%
VANGUARD CAPITAL MANAGEMENT LLC4.21%
ORBIMED ADVISORS LLC3.84%
MACKENZIE FINANCIAL CORP3.75%
FEDERATED HERMES, INC.3.54%
VANGUARD PORTFOLIO MANAGEMENT LLC3.30%
Madison Avenue Partners, LP3.17%
Qube Research & Technologies Ltd3.08%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.01%
iShares Russell 2000 ETF2.55%
BlackRock Advantage Small Cap Core Fund2.29%
Federated Hermes MDT Small Cap Core Fund1.93%
VANGUARD STRATEGIC SMALL-CAP EQUITY FUND1.31%
VANGUARD EXTENDED MARKET INDEX FUND1.12%
Fidelity Small Cap Index Fund1.01%
Nuveen Quant Small Cap Equity Fund0.96%
iShares Russell 2000 Value ETF0.88%
VANGUARD EXPLORER FUND0.86%

OakChart. KROS. Cached 15 minutes.